1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Medanta Partners with Korean Association in India to Enhance Healthcare Access for Korean Community

15 Oct 2025
Admin
News Article

Medanta Partners with Korean Association in India to Enhance Healthcare Access for Korean Community

Medanta, one of India’s leading super-speciality hospitals and ranked the Best Private Hospital in India by Newsweek for six consecutive years, has entered a two-year partnership with The Korean Association in India to deliver advanced healthcare services to Korean nationals living in India.

The Memorandum of Understanding (MoU) was signed at Medanta’s Gurugram campus in late September, in the presence of Dr. Naresh Trehan, Chairman and Managing Director, Medanta, and Kwang-Il Lee, President, The Korean Association in India, along with senior representatives from both organizations.

Partnership Highlights

Under the collaboration, Medanta will extend:

Comprehensive medical care, including OPD consultations, executive preventive health check-ups, and inpatient services.
A dedicated Korean helpdesk and helpline, staffed by a relationship manager for personalized coordination and support.
Green-channel registration and VIP tagging, ensuring a seamless hospital experience for Korean members.

This initiative reinforces Medanta’s mission to make high-quality, compassionate, and culturally attuned healthcare accessible to international communities residing in India.

About Medanta

Founded by Dr. Naresh Trehan, a globally recognized cardiovascular and cardiothoracic surgeon and recipient of the Padma Bhushan, Padma Shri, and Dr. B.C. Roy Award, Medanta operates under Global Health Limited, one of India’s largest private tertiary care providers.

Medanta’s network currently includes six operational hospitals across Gurgaon, Indore, Ranchi, Lucknow, Patna, and Noida, covering 5.5 million sq. ft. and housing 3,362 installed beds as of September 2025.

The group is also expanding with four new hospitals under development in Mumbai, New Delhi (Pitampura), South Delhi (GK), and Guwahati, adding approximately 2,000 more beds to its capacity.

Medanta provides healthcare across 30+ medical specialties, powered by 2,000+ doctors and multidisciplinary teams led by renowned specialists.